Market Overview

J.P. Morgan Reiterates Overweight Rating on Gilead Sciences

Related GILD
Gilead Sciences Get European Commission Grant For Marketing Authorization Of Its Single Tablet Regimen Odefsey
As Buybacks Soar, Buyback ETF Tries To Get Its Groove Back
Thanks BREXIT For Cooling Markets Down (Seeking Alpha)

In a report published Wednesday, J.P. Morgan & Co. reiterated its Overweight rating on Gilead Sciences (NASDAQ: GILD).

J.P. Morgan noted, “This morning, Gilead announced the acquisition of YM Biosciences for approximately $510M ($2.95/share) in cash. The transaction has been unanimously approved by YM's board and is expected to close in 1Q13. YM's lead assed is CYT387, a janus kinase inhibitor (JAK), being developed for myelofibrosis (positive phase 1-2 data). Overall, the transaction makes sense to us given Gilead's recent strategy of expanding into hematology/oncology. Indeed, CYT387 will complement Gilead's current hematology/oncology pipeline which currently includes idelalisib (GS-1101) in phase 3 (CLL/iNHL) and simtuzumab (GS-6624) in phase 2 testing (myelofibrosis, colorectal cancer, pancreatic and certain fibrotic disease). Gilead intends to initiate a phase 3 trial of CYT387 in myelofibrosis in 2H13. We are encouraged by the expanding hematology/oncology pipeline which provides additional shots on goal, beyond the core anti-viral franchise. We reiterate our Overweight rating largely based on a strong core HIV business and a significant opportunity in hep-C, as well as the optionally beyond the anti-viral franchises.”

Gilead Sciences closed on Tuesday at $76.34.

Latest Ratings for GILD

Jun 2016Gabelli & CoInitiates Coverage onBuy
May 2016Morgan StanleyMaintainsEqual-weight
Apr 2016CitigroupMaintainsBuy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: J.P. Morgan & Co.Analyst Color Reiteration Analyst Ratings


Related Articles (GILD)

View Comments and Join the Discussion!